Dyspnoea in advanced malignancies: a palliative care approach
- PMID: 7521608
Dyspnoea in advanced malignancies: a palliative care approach
Abstract
The incidence of dyspnoea in advanced malignancies varies from 48-78.6% in different studies. A systematic approach enables the clinician to separate non-malignant causes from those due to complications of malignancy. Specific treatment should be considered for airway obstruction, secondary chest infection, pleural effusions and superior vena cava obstruction. Morphine remains the most effective drug and may be delivered either orally or by inhalation. Nebulised anaesthetics are alternatives, while the value of other drugs is uncertain. Oxygen therapy and treatment of anxiety are important components.
Similar articles
-
[Symptomatic relief in dyspnoea].Ugeskr Laeger. 2007 Oct 29;169(44):3756-9. Ugeskr Laeger. 2007. PMID: 18028843 Danish.
-
[Symptomatic treatment of dyspnoea in patients receiving palliative care: nasal delivery of oxygen compared with opioid administration].Dtsch Med Wochenschr. 2007 Sep;132(38):1939-43. doi: 10.1055/s-2007-985621. Dtsch Med Wochenschr. 2007. PMID: 17853348 German.
-
Out-of-hospital opioid therapy of palliative care patients with "acute dyspnoea": a retrospective multicenter investigation.J Opioid Manag. 2009 Mar-Apr;5(2):115-22. doi: 10.5055/jom.2009.0013. J Opioid Manag. 2009. PMID: 19507808
-
Management of refractory breathlessness in patients with advanced cancer.Wien Med Wochenschr. 2009 Dec;159(23-24):591-8. doi: 10.1007/s10354-009-0728-y. Wien Med Wochenschr. 2009. PMID: 20151348 Review.
-
Management of Breathlessness in Patients With Advanced Cancer: A Narrative Review.Am J Hosp Palliat Care. 2016 Apr;33(3):286-90. doi: 10.1177/1049909114554796. Epub 2014 Oct 15. Am J Hosp Palliat Care. 2016. PMID: 25318928 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical